pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,214 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1203Endpoints912BioPharma Dive351BioSpace330Fierce Biotech308onclive165raps110globenewswire health73
therapy area
allOncology7947Rare Disease1912Cardiology1843Immunology1532Hematology1342Pulmonology1239Vaccines
  • BioNTech plans to cut up to 1,860 manufacturing jobs as it scales down production footprint
    BioNTech announced in its first‑quarter earnings release that it will reduce its manufacturing footprint. The company said the restructuring could affect as many as 1,860 employees working in its…
    Endpoints · 4mo agoLayoffsNegative↗ source
  • Viridian's elegrobart shows strong results in chronic thyroid eye disease trial, challenging Amgen's Tepezza
    Viridian Therapeutics announced that its injectable drug elegrobart met its primary goals in a late-stage study of patients with chronic thyroid eye disease. The trial reported response rates of 50…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
← prev
page 119 of 129
next →
fda medwatch67
fda recalls65
fda press38
1231
Psychiatry & CNS882
Ophthalmology517
Pain497
Endocrinology & Metabolism487
Infectious Disease455
  • Pfizer halts final Trillium study, redirects R&D funds to cancer and obesity programs
    Pfizer announced it is ending the last clinical trial that originated from its 2021 purchase of Trillium Therapeutics. The company said the decision will free up cash that will be redirected to a…
    Endpoints · 4mo agoNeutral↗ source
  • Madrigal secures fourth MASH partnership, snapping up Arrowhead drug passed over by J&J
    Madrigal Pharmaceuticals announced its latest collaboration, marking the fourth deal focused on metabolic dysfunction-associated steatohepatitis (MASH) within a ten‑month span. The agreement bring…
    Endpoints · 4mo agoDealPositive↗ source
  • Cytokinetics' HCM drug shows positive trial results, potentially doubling market after Bristol Myers' setback
    Cytokinetics announced that its oral therapy for hypertrophic cardiomyopathy (HCM) achieved positive results in a pivotal trial targeting a different form of the disease. The data suggest the drug…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Pharma's reputation among patient groups edges up to 57% but access and pricing concerns linger
    Patient groups surveyed by research firm PatientView gave drugmakers a 57% “good” or “excellent” reputation rating, the highest level since 2023. The survey covered more than 2,400 groups in 35 cou…
    STAT · 4mo agoNeutral↗ source
  • GOP Oversight Chair James Comer Targets AMA Billing Codes Over Fraud Concerns
    House Oversight Committee Chair James Comer, a Republican from Kentucky, is directing new scrutiny toward the American Medical Association's Current Procedural Terminology (CPT) billing codes, alle…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Microbiome startup Kanvas Biosciences secures $48 million to advance immunotherapy and malnutrition therapies
    Kanvas Biosciences announced it has closed a $48 million financing round to fund development of microbiome-based treatments targeting cancer immunotherapy response and severe malnutrition. The cap…
    Endpoints · 4mo agoDealPositive↗ source
  • J&J advances IBD combo to Phase 3 despite Phase 2 setbacks
    Johnson & Johnson said it will advance its experimental inflammatory bowel disease therapy, JNJ-4804, into Phase 3 trials even though the drug failed to meet primary endpoints in two Phase 2 studie…
    Endpoints · 4mo agoNegative readoutNeutral↗ source
  • Cytospire secures $83 million to develop pan-gamma delta T-cell engagers
    Cytospire, a British biotechnology startup, announced it raised £61 million, about $83 million, to fund the development of a new type of T-cell engager therapy. The company is targeting a "pan-gam…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • STAT+ examines AI diagnostic claims, telehealth abortion access and Epic lawsuit in latest health tech newsletter
    STAT+ published a health‑tech newsletter that asks whether artificial intelligence has truly outperformed physicians in diagnosing disease, citing a high‑profile study on AI diagnostic performance.…
    STAT · 4mo agoNeutral↗ source
  • Parsley Health joins nationwide insurance networks, expanding access to its primary-care model
    Parsley Health, a decade-old primary-care startup that originally operated on a cash-pay model, announced that it is now in-network with insurers across the United States. The move marks a shift f…
    Endpoints · 4mo agoPositive↗ source
  • Takeda advances gene therapy, UK cancer biotech raises $83M, and new blood test may guide Wegovy use
    A Cleveland‑based biotech announced that a previously halted gene therapy program has been revived, offering a potential new option for patients as the company pursues additional studies. Takeda r…
    Endpoints · 4mo agoNeutral↗ source
  • Swiss pharma manufacturing remains steady despite tariff threats, impact may take years
    Swiss biotech day event highlighted that pharma manufacturing in Switzerland shows no immediate disruption from geopolitical tensions or potential tariffs. Industry representatives said that while…
    Endpoints · 4mo agoNeutral↗ source
  • Healthcare giants increasingly develop in-house AI tools instead of buying from startups
    Panelists at the Digital Healthcare Innovation Summit in Boston highlighted a growing shift among large health‑care organizations toward creating their own artificial‑intelligence solutions. Rather…
    Endpoints · 4mo agoNeutral↗ source
  • RFK Jr. proposes steps to curb SSRI prescriptions; J&J pushes IBD drug; French regulators fine Novo, Lilly over weight-loss ads
    U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a set of initiatives aimed at reducing the prescribing of selective serotonin reuptake inhibitors, the most widely used clas…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • STAT+: Top lawmaker takes aim at doctor lobby, linking AMA’s billing codes to fraud fight
    A top Republican is asking if the AMA's codes are helping to fuel health care fraud.
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Intercept’s next-generation FXR agonist INT-787 fails Phase 2 trial in alcohol-associated hepatitis
    Intercept Pharmaceuticals reported that its experimental FXR agonist INT-787 did not demonstrate efficacy in a Phase 2 study of patients with severe alcohol-associated hepatitis. The trial results…
    Endpoints · 4mo agoNegative readoutNegative↗ source
  • Supreme Court temporarily restores broad access to abortion pill mifepristone
    The Supreme Court issued an order on Monday that temporarily reinstates wide availability of the abortion medication mifepristone. The order follows a federal appeals court decision that had threat…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Returning doctors face unexpected hurdles and new chances to improve care in their home countries
    The opinion piece argues that the common "brain drain" story about health workers leaving low‑income nations overlooks what happens when they come back. The author cites a breast surgeon who train…
    STAT · 4mo agoNeutral↗ source
  • China's new supply chain rules threaten Western pharma as Beijing tightens control over biotech imports
    China has rapidly expanded its role in drug development, moving from less than 8% of global clinical trials in 2010 to overtaking the United States in trial volume by 2020, with more than 5,000 tri…
    STAT · 4mo agoRegulatoryNegative↗ source
  • French regulator fines Novo Nordisk and Eli Lilly for misleading weight loss ads
    French medicines regulator ANSM imposed fines on Novo Nordisk and Eli Lilly for advertising practices linked to their weight loss drugs. Novo Nordisk was fined about $2 million for ads promoting W…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Celcuity reports positive Phase 3 results for gedatolisib in PIK3CA-mutant breast cancer
    On May 4, 2026 Celcuity announced that its experimental drug gedatolisib achieved success in two treatment regimens for patients whose tumors carry PIK3CA mutations, according to data from its ongo…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Latus Bio raises $97 million to advance gene therapies for Huntington’s and Batten disease
    Latus Bio announced closing a $97 million Series A round, including a $43 million extension to a prior $54 million raise. Funding was led by 8VC and included eight other investors such as DCVC Bio…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • UCB to buy Candid Therapeutics for up to $2.2 billion, targeting bispecific antibodies for autoimmune disease
    UCB announced a deal to acquire Candid Therapeutics, a startup focused on bispecific antibody drugs, for an upfront payment of $2 billion with up to $200 million in future milestones. The transacti…
    BioPharma Dive · 4mo agoDealPositive↗ source